Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by 87c; Guides
February 23, 2022 4:18 PM ESTFulgent Genetics, Inc. (NASDAQ: FLGT) reported Q4 EPS of $3.48, $0.87 better than the analyst estimate of $2.61. Revenue for the quarter came in at $251.7 million versus the consensus estimate of $191.1 million.
GUIDANCE:
Fulgent Genetics, Inc. sees Q1 2022 revenue of ~$245 million, versus the... More
